Axa S.A. Verastem, Inc. Transaction History

Axa S.A.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 13, 2019	SELL	$1.25 - $3.14 $29,250 - $73,476	-23,400 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$2.79 - $4.09 $65,286 - $95,706	23,400 New	23,400 $69,000
Q3 2018 Nov 08, 2018	SELL	$6.86 - $9.97 $162,582 - $236,289	-23,700 Closed	0 $0
Q2 2018 Aug 13, 2018	SELL	$2.88 - $8.67 $157,608 - $474,465	-54,725 Reduced 69.78%	23,700 $163,000
Q4 2017 Feb 13, 2018	BUY	$2.99 - $4.85 $57,162 - $92,722	19,118 Added 32.24%	78,425 $241,000
Q3 2017 Nov 13, 2017	BUY	$3.01 - $5.41 $178,514 - $320,850	59,307	59,307 $279,000

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $603M
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.